LEADER 04378nam 2200721 450 001 9910785707703321 005 20200520144314.0 010 $a0-231-53127-3 024 7 $a10.7312/kahn16298 035 $a(CKB)2670000000314982 035 $a(EBL)1028090 035 $a(OCoLC)818814876 035 $a(SSID)ssj0000785124 035 $a(PQKBManifestationID)11501075 035 $a(PQKBTitleCode)TC0000785124 035 $a(PQKBWorkID)10804126 035 $a(PQKB)10175167 035 $a(StDuBDS)EDZ0000101029 035 $a(DE-B1597)458982 035 $a(OCoLC)979626630 035 $a(DE-B1597)9780231531276 035 $a(Au-PeEL)EBL1028090 035 $a(CaPaEBR)ebr10975960 035 $a(CaONFJC)MIL666243 035 $a(MiAaPQ)EBC1028090 035 $a(EXLCZ)992670000000314982 100 $a20141121h20132013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aRace in a bottle $ethe story of BiDil and racialized medicine in a post-genomic age /$fJonathan Kahn ; cover design by David Drummond 210 1$aNew York ;$aChichester, England :$cColumbia University Press,$d2013. 210 4$dİ2013 215 $a1 online resource (329 p.) 300 $aIncludes index. 311 $a1-322-34961-4 311 $a0-231-16298-7 320 $aIncludes bibliographical references and index. 327 $tFrontmatter -- $tContents -- $tAcknowledgments -- $tINTRODUCTION: Race and Medicine: Framing [Is] the Problem -- $t1. Organizing race -- $t2. The Birth of Bidil -- $t3. Statistical Mischief and Racial Frames for Drug Development and Marketing -- $t4. Capitalizing [on] Race in Drug Development -- $t5. Race-ing Patents/ Patenting Race -- $t6. Not Fade Away -- $t7. From Disparity to Difference -- $tConclusions and Recommendations -- $tNotes -- $tIndex 330 $aAt a ceremony announcing the completion of the first draft of the human genome in 2000, President Bill Clinton declared, "I believe one of the great truths to emerge from this triumphant expedition inside the human genome is that in genetic terms, all human beings, regardless of race, are more than 99.9 percent the same." Yet despite this declaration of unity, biomedical research has focused increasingly on mapping that.1 percent of difference, particularly as it relates to race.This trend is exemplified by the drug BiDil. Approved by the FDA in 2005 as the first drug with a race-specific indication on its label, BiDil was originally touted as a pathbreaking therapy to treat heart failure in black patients and help underserved populations. Upon closer examination, however, Jonathan Kahn reveals a far more complex story. At the most basic level, BiDil became racial through legal maneuvering and commercial pressure as much as through medical understandings of how the drug worked. Using BiDil as a central case study, Kahn broadly examines the legal and commercial imperatives driving the expanding role of race in biomedicine, even as scientific advances in genomics could render the issue irrelevant. He surveys the distinct politics informing the use of race in medicine and the very real health disparities caused by racism and social injustice that are now being cast as a mere function of genetic difference. Calling for a more reasoned approach to using race in biomedical research and practice, Kahn asks readers to recognize that, just as genetics is a complex field requiring sensitivity and expertise, so too is race, particularly in the field of biomedicine. 606 $aHydralazine$xDevelopment$xHistory 606 $aHealth and race 606 $aAfrican Americans$xMedical care 606 $aPharmacogenetics$xSocial aspects 606 $aPharmaceutical industry$xPolitical aspects$zUnited States 615 0$aHydralazine$xDevelopment$xHistory. 615 0$aHealth and race. 615 0$aAfrican Americans$xMedical care. 615 0$aPharmacogenetics$xSocial aspects. 615 0$aPharmaceutical industry$xPolitical aspects 676 $a616.1/2906108996073 686 $aCC 7264$2rvk 700 $aKahn$b Jonathan$01548558 702 $aDrummond$b David 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910785707703321 996 $aRace in a bottle$93805666 997 $aUNINA